ADHFE1 (Alcohol Dehydrogenase Iron-Containing 1), also known as hydroxyacyl-coenzyme A dehydrogenase homolog (HADH2), is a mitochondrial enzyme involved in metabolic pathways, particularly the oxidation of D-3-hydroxybutyrate and other short-chain hydroxyacyl-CoAs. It plays a role in ketone body metabolism and fatty acid oxidation. ADHFE1 is structurally classified within the iron-containing alcohol dehydrogenase family, characterized by its conserved catalytic iron-binding motifs. Dysregulation of ADHFE1 has been linked to metabolic disorders and cancer, with studies suggesting its overexpression in certain tumors, such as gliomas and breast cancers, where it may influence cellular energy metabolism and tumor progression.
ADHFE1 antibodies are essential tools for studying the protein’s expression, localization, and function. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect ADHFE1 in tissues or cell lysates. Commercially available antibodies are typically validated for specificity against human, mouse, or rat ADHFE1. Research applications include investigating metabolic reprogramming in cancer, mitochondrial dysfunction, and the enzyme’s role in ketolysis. Some studies also explore ADHFE1 as a potential biomarker or therapeutic target in metabolic syndromes and malignancies. Proper validation using knockout controls or siRNA knockdown is recommended to confirm antibody specificity due to potential cross-reactivity with homologous proteins.